Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain

• DOI: 10.1016/j.nefro.2021.03.006
• Publication Date: 2021-06-18T08:04:06Z
• Authors: Carlos Escobar; Unai Aranda; Beatriz Palacios; Margarita Capel; Antoni Sicras; Aram Sicras; Antonio Hormigo; Roberto Alcázar; Nicolás Manito; Manuel Botana
• Keywords: Male; Epidemiology; Hospitalización; Eventos; Medication; Medicación; 03 medical and health sciences; 0302 clinical medicine; Chronic kidney disease; Albumins; Prevalence; Diabetes Mellitus; Malalties cròniques; Humans; Renal Insufficiency, Chronic; Epidemiologia; Enfermedad renal crónica; Sodium-Glucose Transporter 2 Inhibitors; Inhibition; Outcome; Retrospective Studies; Heart Failure; Kidney diseases; DAPA-CKD; Esc guidelines; Diseases of the genitourinary system. Urology; Death; Hospitalization; Muerte; Spain; Chronic diseases; Creatinine; Malalties del ronyó; Female; RC870-923

To describe the epidemiology, clinical profile, treatments, and to determine cardiovascular and renal outcomes after two years of follow-up in a contemporary chronic kidneay disease (CKD) population in Spain. This was also analyzed among the DAPA-CKD-like population (patients who met most inclusion criteria of DAPA-CKD trial).Observational, retrospective, population-based study using BIG-PAC database. The CKD population was defined as patients ≥18 years, with at least one diagnostic code of CKD prior to the index date (January 1st, 2018). CKD was defined as estimated glomerular filtration rate (eGFR) <60mL/min/1.73m2 (CKD-EPI), or albuminuria >30mg/g.We identified 56,435 CKD patients after exclusions (76.4 years, 52.2% men, urine albumin-to-creatinine ratio 390.8mg/g, eGFR 49.7mL/min/1.73m2). CKD prevalence was 4.91% and incidence 2.10 per 1000 patient-years. Regarding treatments, 69.2% were taking renin-angiotensin system inhibitors (only 4.2% at maximal doses) and 3.5% of diabetic patients SGLT-2 inhibitors. During the two years of follow-up, rates of heart failure, all-cause death, myocardial infarction, stroke, and CKD were 17.9, 12.1, 7.2, 6.3, and 5.9 events per 100 patient-years, respectively. During this period, 44% of patients were hospitalized, and 6.8% died during hospitalization. Cardiovascular outcomes were more common in the DAPA-CKD-like population.In Spain, CKD population is older and comorbidities, including diabetes and heart failure, are common. Cardiovascular and renal outcomes are frequent. There is room for improvement in CKD management, particularly through the use of drugs with proven cardiovascular and renal benefit.